Healthcare

STAAR Surgical sells implantable lenses for vision correction, centered on the EVO ICL franchise. The company operates in a market supported by rising myopia and premium eye-care demand, while recent results point to a potentially meaningful recovery if execution and margins improve.

Savara is a rare-disease biotech centered on an inhaled therapy for autoimmune PAP. The appeal lies in its focused strategy, visible regulatory milestones, and the possibility of shifting from clinical-stage spending to commercial revenue if launch plans materialize.

Seaport Therapeutics is building a neuroscience pipeline for depression and related disorders, using a platform intended to improve known drug mechanisms. Its clean balance sheet and large target markets stand out, while clinical progress remains the key factor behind its valuation.

Summerset runs retirement villages and aged-care facilities in New Zealand, combining recurring care income with development-driven growth. Revenue and asset value have grown strongly, while a very low valuation shows how much the market is discounting property and financing pressure.

Safilo is a global eyewear group reshaping itself around stronger margins, low debt, and a more controlled brand portfolio. The business has regained profitability and cash flow strength, making its long-term positioning more interesting than in earlier years.

Ryman Healthcare runs retirement villages and aged-care facilities in New Zealand and Australia. Demand is backed by aging populations, and revenue has continued to grow. The key question is whether solid cash generation and valuable assets can translate back into durable profitability.

Replimune is developing virus-based cancer immunotherapies, with RP1 as its lead asset. The company sits in a fast-growing oncology field, and its platform could gain value if upcoming clinical and regulatory milestones rebuild the path to commercialization.